## INCY: Incyte Corporation - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 0.13 indicates fundamental undervaluation. Quality metrics strong (ROE 30%, ROA 14%). Consistent execution (3/4 quarters beat estimates). Caution: declining volume (36% of avg), momentum weakening (-2.3% MRS).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($94.27)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 5
- **Sentiment:** Bullish (Bullish: 2, Bearish: 0)

**1. Incyte Corp Principal Accounting Officer Sells Shares**
- Source: TradingView — Track All Markets | 20251224T011040 | Somewhat-Bearish | Relevance: 100%
- Tray Thomas, Principal Accounting Officer and 10% Owner of Incyte Corp (INCY), sold 3,374 shares of common stock on December 18 and 19, 2025, for a total of $336,350. The sales were made at prices of $98.25 and $100.00 per share. Following these transactions, Thomas directly owns 22,973 shares of Incyte Corp.

**2. Cwm LLC Buys 65,292 Shares of Incyte Corporation $INCY**
- Source: MarketBeat | 20251228T090423 | Bullish | Relevance: 100%
- Cwm LLC increased its stake in Incyte Corporation (NASDAQ: INCY) by 49.8% in Q3, acquiring 65,292 shares to hold a total of 196,472 shares valued at approximately $16.66 million. Incyte recently outperformed earnings expectations, reporting an EPS of $2.26 against an anticipated $1.65, and revenues of $1.37 billion. Despite a consensus "Hold" rating from analysts, several firms have raised their price targets for the biopharmaceutical company.

**3. Swedbank AB Decreases Stock Holdings in Incyte Corporation $INCY**
- Source: MarketBeat | 20251226T105207 | Neutral | Relevance: 100%
- Swedbank AB has reduced its holdings in Incyte Corporation by 39.2% in the third quarter of 2025, selling 239,438 shares and now owning 371,856 shares valued at approximately $31.54 million. Despite this, Incyte exceeded Q3 earnings expectations, reporting an EPS of $2.26 and revenue of $1.37 billion, marking a 20% year-over-year increase. Analysts maintain a "Hold" rating on Incyte with an average price target of $99.79, while company insiders have also sold a significant number of shares recently.

**4. Vitiligo Drugs Market Strategic Outlook Through 2032 Based**
- Source: openPR.com | 20251226T110812 | Bullish | Relevance: 100%
- The Vitiligo Drugs Market is projected to experience substantial growth from 2025 to 2032, driven by rising demand, technological advancements, and expanding applications. The report provides a comprehensive analysis of market size, revenue trends, key growth factors, and competitive landscape, offering actionable insights for strategic decision-making. Leading companies in this market include Dermavant Sciences Inc., Incyte Corporation, and Pfizer Inc.

**5. CRISPR Therapeutics (CRSP): Reassessing Valuation After Positive Zugo‑cel Data and New Eli Lilly Collaboration**
- Source: Simply Wall Street | 20251225T230946 | Neutral | Relevance: 59%
- CRISPR Therapeutics (CRSP) has provided positive updates on its off-the-shelf CAR T therapy, zugo-cel, including strong early responses, clean safety signals, and a new collaboration with Eli Lilly. Despite a recent share price recovery, the stock appears undervalued according to Simply Wall St's DCF model, suggesting a potential discount of over 55% compared to its fair value estimate of $126.78. The company's price-to-book ratio is slightly higher than the US biotech industry average but significantly lower than its peer group, indicating that the market may still be discounting its growth prospects.

### Analyst Activity

**Target Signal:** VERY_BULLISH (Raises: 3, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-08 | Morgan Stanley | $92 | $86 | +7% |
| 2025-12-08 | Wells Fargo | $116 | $97 | +20% |
| 2025-12-08 | Mizuho | $121 | $90 | +34% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-08 | Morgan Stanley | main | Equal-Weight |
| 2025-12-08 | Wells Fargo | main | Overweight |
| 2025-12-08 | Mizuho | up | Outperform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 4 ($0.05M) |
| Sells | 20 ($25.81M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 59.2% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 5 |

**Top Holders:**
- Baker Bros. Advisors: 15.7% (0.0%)
- Vanguard Group Inc: 10.2% (-0.9%)
- Blackrock Inc.: 9.1% (-0.3%)
- Dodge & Cox Inc.: 7.1% (-4.5%)
- State Street Corpora: 4.9% (-2.0%)

### Key Risks

1. Heavy insider selling: $26M sold (20 transactions in 90 days).
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Analyst target momentum: 3 raises (avg +20%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.13 indicates undervaluation relative to growth. Forward P/E 13.1x attractive for 14% earnings growth. Quality metrics strong (ROE 30%, ROA 14%, margin 25%). Balance sheet: strong liquidity (3.2x), low leverage (D/E 0.36). Analyst sentiment positive (3 raises, avg +20%). Insider selling cluster ($25.8M in 90 days), potential headwind. Institutional flow bullish (4 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $19.7B |
| Beta | 0.81 |
| 52W Range | $53.56 - $109.28 |
| Short Interest | 7.7% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.13 |
| Forward P/E | 13.1 |
| Current P/E | 14.9 |
| YoY Growth | 13.7% |
| EPS Direction | RISING |

### Technicals

MRS_20 deteriorating from 2.1% to -0.1% (-2.3% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 4.1pp (needs >4.0% for momentum thesis). Full SMA alignment bullish (above 20/50/200 SMAs). RSI neutral at 52. Volume at 36% of 20MA suggests lack of conviction. OFD pattern: -SLL (Support test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -0.14% (CS: 51) | Neutral |
| RSI_14 | 51.7 | Neutral |
| MACD Histogram | 0.16 | Bullish |
| vs SMA20 | 1.008x | Above |
| vs SMA50 | 1.012x | Above |
| vs SMA200 | 1.276x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $100.11
- **Stop Loss:** $94.27 (5.8% risk)
- **Target:** $111.79 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 226
- **Position Value:** $22,624.86
- **Portfolio %:** 22.62%
- **Risk Dollars:** $1,320.00
- **Risk Per Trade:** 1.32%
- **Modifiers:** L1 110% | L2 120% | Combined 1.32x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.10x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with selective risk appetite amid holiday trading. VIX at extreme lows (13.6) signals complacency while positive yield curve (+59bps) and stable economic data support continuation. Focus on quality names with AI/infrastructure exposure while monitoring January volatility reset.*

### Earnings

**Next:** 2026-02-09 (Est: $1.89)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.64 | $2.26 | +38.0% |
| 2025Q2 | $1.47 | $1.57 | +6.6% |
| 2025Q1 | $1.03 | $1.16 | +12.3% |
| 2024Q4 | $1.55 | $1.43 | -8.0% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_20*